- Home
- MURA vs CCM Comparison
MURA vs CCM Comparison
Compare MURA & CCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- CCM
- Stock Information
- Founded
- MURA 2013
- CCM 1997
- Country
- MURA Ireland
- CCM China
- Employees
- MURA N/A
- CCM N/A
- Industry
- MURA
- CCM Medical/Nursing Services
- Sector
- MURA
- CCM Health Care
- Exchange
- MURA Nasdaq
- CCM Nasdaq
- Market Cap
- MURA 35.7M
- CCM 33.3M
- IPO Year
- MURA N/A
- CCM 2009
- Fundamental
- Price
- MURA $2.08
- CCM $5.64
- Analyst Decision
- MURA Strong Buy
- CCM
- Analyst Count
- MURA 3
- CCM 0
- Target Price
- MURA $12.00
- CCM N/A
- AVG Volume (30 Days)
- MURA 497.8K
- CCM 3.0K
- Earning Date
- MURA 08-04-2025
- CCM 09-26-2025
- Dividend Yield
- MURA N/A
- CCM N/A
- EPS Growth
- MURA N/A
- CCM N/A
- EPS
- MURA N/A
- CCM N/A
- Revenue
- MURA N/A
- CCM $52,603,198.00
- Revenue This Year
- MURA N/A
- CCM N/A
- Revenue Next Year
- MURA N/A
- CCM N/A
- P/E Ratio
- MURA N/A
- CCM N/A
- Revenue Growth
- MURA N/A
- CCM N/A
- 52 Week Low
- MURA $0.95
- CCM $3.80
- 52 Week High
- MURA $4.74
- CCM $10.77
- Technical
- Relative Strength Index (RSI)
- MURA 52.06
- CCM 55.42
- Support Level
- MURA $2.05
- CCM $5.10
- Resistance Level
- MURA $2.09
- CCM $5.99
- Average True Range (ATR)
- MURA 0.01
- CCM 0.14
- MACD
- MURA 0.02
- CCM 0.04
- Stochastic Oscillator
- MURA 62.50
- CCM 60.67
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.